Results 111 to 120 of about 111,447 (309)

Pattern and management of antihypertensive drug toxicity among admitted patients to Alexandria poison center, Egypt [PDF]

open access: yesAsia Pacific Journal of Medical Toxicology
Background: Despite different antidotes, antihypertensive toxicity, especially beta-blockers (BB) and calcium channel blockers (CCB), have a significant morbidity and mortality.
Maha Ghanem   +4 more
doaj   +1 more source

Pharmacological treatment for patients with obesity and heart failure: Focus on glucagon‐like peptide‐1 receptor agonists. European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
There is growing clinical interest in strategies for improving clinical outcomes in patients with heart failure (HF) and obesity. The development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and of the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 RA has expanded therapeutic options for this population. This expert consensus
Luca Monzo   +13 more
wiley   +1 more source

Achieved systolic blood pressure in older people: a systematic review and meta-analysis

open access: yesBMC Geriatrics, 2017
Background It remains unclear into which level the systolic blood pressure (SBP) should be lowered in order to provide the best cardiovascular protection among older people. Hypertension guidelines recommendation on attaining SBP levels
Aline A. I. Moraes   +11 more
doaj   +1 more source

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document

open access: yesEuropean Journal of Heart Failure, EarlyView.
Main categories of harmful drugs in heart failure. CCB, calcium channel blocker; DPP4i, dipeptidyl peptidase‐4 inhibitor; HER2‐TT, human epidermal growth factor receptor 2‐targeted therapy; NSAID, non‐steroidal anti‐inflammatory drug; TKI, tyrosine kinase inhibitor; TZD, thiazolidinedione; VEGF Inh, vascular endothelial growth factor inhibitor.
Amr Abdin   +16 more
wiley   +1 more source

FK506 IN PEDIATRIC KIDNEY-TRANSPLANTATION - PRIMARY AND RESCUE EXPERIENCE [PDF]

open access: yes, 1995
Between December 14, 1989, and December 17, 1993,43 patients undergoing kidney transplantation alone at the Children’s Hospital of Pittsburgh received FK506 as the primary immunosuppressive agent. The mean recipient age was 10.2 ± 4.8 years (range 0.7–17.
ELLIS, D   +13 more
core   +1 more source

Adherence to guideline‐directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy

open access: yesEuropean Journal of Heart Failure, EarlyView.
Heart failure (HF) affects over 60 million individuals globally. Contemporary guideline‐directed medical therapies (GDMT) reduce cardiovascular mortality and HF hospitalizations. However, medication non‐adherence represents a critical barrier limiting real‐world efficacy of GDMT.
Gianluigi Savarese   +37 more
wiley   +1 more source

Asymmetric Catalytic Hydrogenation toward a Value‐Added Chiral Building Block: Optically Active γ‐Butyrolactone Scaffold from Renewable and Synthetic Derived Feedstocks

open access: yesEuropean Journal of Organic Chemistry, EarlyView.
This brief compendium summarizes the most successful asymmetric hydrogenation strategies for the preparation of chiral monocyclic γ‐lactone derivatives from keto acids and keto esters, with emphasis on their relevance for large‐scale production and high enatioselectivities. This article provides a brief compendium on the production of chiral monocyclic
Marta Feliz, Maria J. Sabater
wiley   +1 more source

Home - About - Disclaimer - Privacy